15. Schering-Plough - Top 15 R&D Budgets

Who: Schering-Plough

Based: United States

2006 Pipeline Budget: $2.14 billion (€1.65B)

2007 Pipeline News: When Fred Hassan came to Schering-Plough in 2003, the company was in a tough spot, to say the least. Schering's blockbuster drug Claritin had lost patent protection and there was almost nothing else in the pipeline to pick up the slack. The company had been cited for manufacturing lapses, and there was an SEC probe along with questions about Medicare fraud.

Four years later, Schering-Plough looks like a whole new company. Hassan has won kudos all around for the company's amazing turn-around, impressing analysts with what many consider to be one of the strongest pipelines in the industry. The recent purchase of Azko Nobel's Organon added five more late-stage drugs to the company's roster. Most recently, the FDA accepted Schering-Plough's application for asenapine, a tablet for schizophrenia and bipolar disorder.

Pending Approval:

ASMANEX - Asthma (Japan), Pediatric Asthma
CLARITIN/Singulair2 - Seasonal Allergic Rhinitis
NASONEX - Allergic Rhinitis (Japan)
NOXAFIL - Serious Fungal Infections

Phase III:

> Acadesine - Ischemia-Reperfusion Injury
> ASENTAR - Prostate Cancer
> Golimumab (CNTO 148) - Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis
> Mometasone/Formoterol Combination - Asthma, COPD
> SARASAR - Myelodysplastic Syndrome
> Sublingual Tablet-Based Immunotherapy - Grass Pollen Allergies
> Thrombin Receptor Antagonist - ACS / Secondary Prevention
> Vicriviroc - HIV Infection
> CAELYX1 - Multiple Myeloma (EU)
> INTEGRILIN - Early Acute Coronary Syndrome
> NASONEX - Rhinosinusitis
> PEGINTRON - Malignant Melanoma
> TEMODAR - Metastatic Melanoma
> VYTORIN2 - Aortic Stenosis, Renal Disease, High Risk Hypercholesterolemia, Acute Coronary Syndrome
> ZETIA2 - Pediatric Primary Hypercholesterolemia

Full Pipeline Site: Link

15. Schering-Plough - Top 15 R&D Budgets
Read more on

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i